Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix™)
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix™)
Authors
Keywords
-
Journal
DRUGS
Volume 72, Issue 18, Pages 2407-2430
Publisher
Springer Nature
Online
2012-12-12
DOI
10.2165/11209580-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MenACWY-TT vaccine for active immunization against invasive meningococcal disease
- (2012) Vassiliki Papaevangelou et al. Expert Review of Vaccines
- The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine
- (2012) Ghassan Dbaibo et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Increase of meningococcal serogroup Y cases in Europe: A reason for concern?
- (2012) Michael Bröker et al. Human Vaccines & Immunotherapeutics
- An evaluation of emerging vaccines for childhood meningococcal disease
- (2011) Debajeet Choudhuri et al. BMC PUBLIC HEALTH
- Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century
- (2011) Paula Kriz et al. Expert Review of Vaccines
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents
- (2011) Christopher J. Gill et al. Human vaccines & immunotherapeutics
- Cost impact of complications in meningococcal disease: Evidence from a United States managed care population
- (2011) Keith L. Davis et al. Human vaccines & immunotherapeutics
- Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults
- (2011) Nancy Bermal et al. Human vaccines & immunotherapeutics
- Bacterial Meningitis in the United States, 1998–2007
- (2011) Michael C. Thigpen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile
- (2011) Ziad A. Memish et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
- (2011) Roger Baxter et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers
- (2011) Jodie McVernon et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children
- (2011) Markus Knuf et al. VACCINE
- Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial
- (2011) Timo Vesikari et al. VACCINE
- A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial
- (2011) Lars Østergaard et al. VACCINE
- Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®)
- (2010) Emma D. Deeks BIODRUGS
- Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
- (2010) H. Campbell et al. Clinical and Vaccine Immunology
- Epidemiological Profile of Meningococcal Disease in the United States
- (2010) Lee H. Harrison CLINICAL INFECTIOUS DISEASES
- Optimizing Protection Against Meningococcal Disease
- (2010) Keith S. Reisinger et al. CLINICAL PEDIATRICS
- Advances in the Development of Vaccines againstNeisseria meningitidis
- (2010) Lionel K.K. Tan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease
- (2009) Amanda C. Cohn et al. CLINICAL INFECTIOUS DISEASES
- Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
- (2009) Caroline L Trotter et al. Expert Review of Vaccines
- Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution
- (2009) F. Marc LaForce et al. VACCINE
- Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages
- (2009) Michael Bröker et al. VACCINE
- Global epidemiology of meningococcal disease
- (2009) Lee H. Harrison et al. VACCINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search